Cinacalcet Hydrochloride | CAS#364782-34-3 | Allosteric Activator of CaSR

MedKoo Cat#: 317529 | Name: Cinacalcet Hydrochloride

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cinacalcet Hydrochloride is a type II calcimimetic agent which controls calcium levels in cells by allosteric activation of CaSR. In the presence of calcium ions, it can inhibit parathyroid hormone secretion by activating CaSR in parathyroid glands. Studies show that Cinacalcet Hydrochloride affects cell proliferation in CHO cells transfected with CaSRs. In addition, it is known that Cinacalcet Hydrochloride inhibits the secretion of the parathyroid hormone (PTH). Cinacalcet has been used clinically to treat secondary hyperparathyroidism due to end-stage renal disease or hypercalcemia in patients with parathyroid carcinoma.

Chemical Structure

Cinacalcet Hydrochloride

CAS#364782-34-3 (HCl)

Theoretical Analysis

MedKoo Cat#: 317529

Name: Cinacalcet Hydrochloride

CAS#: 364782-34-3 (HCl)

Chemical Formula: C22H23ClF3N

Exact Mass: 0.0000

Molecular Weight: 393.87

Elemental Analysis: C, 67.09; H, 5.89; Cl, 9.00; F, 14.47; N, 3.56

Price and Availability

Size	Price	Availability
1g	USD 250.00	2 Weeks
2g	USD 400.00	2 Weeks
5g	USD 850.00	2 Weeks
10g	USD 1,350.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

364782-34-3 (HCl) 226256-56-0 (free base)

Synonym

Cinacalcet Hydrochloride; Sensipar; Cinacalcet HCl; Mimpara; Regpara; cinacalcet; cinacalcet hydrochloride; Hydrochloride, Cinacalcet; KRN 1493;

IUPAC/Chemical Name

N-[(1R)-1-naphthalen-1-ylethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine;hydrochloride

InChi Key

QANQWUQOEJZMLL-PKLMIRHRSA-N

InChi Code

InChI=1S/C22H22F3N.ClH/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25;/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3;1H/t16-;/m1./s1

SMILES Code

C[C@H](C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F.Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 393.87 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Del Prete M, Marotta V, Ramundo V, Marciello F, Di Sarno A, Esposito R, Carratù AC, De Luca Di Roseto C, Di Somma C, Colao A, Faggiano A. Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1. Minerva Endocrinol. 2013 Dec;38(4):389-94. PubMed PMID: 24285106. 2: Yousaf F, Charytan C. Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism. Ren Fail. 2014 Feb;36(1):131-8. doi: 10.3109/0886022X.2013.832319. Epub 2013 Sep 24. Review. PubMed PMID: 24060145. 3: Yamada S, Tokumoto M, Taniguchi M, Toyonaga J, Suehiro T, Eriguchi R, Fujimi S, Ooboshi H, Kitazono T, Tsuruya K. Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism. Ther Apher Dial. 2015 Aug;19(4):367-77. doi: 10.1111/1744-9987.12292. Epub 2015 Apr 7. PubMed PMID: 25851690. 4: Verheyen N, Pilz S, Eller K, Kienreich K, Fahrleitner-Pammer A, Pieske B, Ritz E, Tomaschitz A. Cinacalcet hydrochloride for the treatment of hyperparathyroidism. Expert Opin Pharmacother. 2013 Apr;14(6):793-806. doi: 10.1517/14656566.2013.777041. Epub 2013 Mar 4. Review. PubMed PMID: 23452174. 5: Nagano N, Ando T, Ito K, Yoshitaka A. [Cinacalcet hydrochloride and phosphate metabolism]. Clin Calcium. 2012 Oct;22(10):1567-76. Review. Japanese. PubMed PMID: 23023638. 6: Koda R, Kazama JJ, Matsuo K, Kawamura K, Yamamoto S, Wakasugi M, Takeda T, Narita I. Intact parathyroid hormone and whole parathyroid hormone assay results disagree in hemodialysis patients under cinacalcet hydrochloride therapy. Clin Exp Nephrol. 2015 Aug;19(4):710-7. doi: 10.1007/s10157-014-1045-3. Epub 2014 Nov 11. PubMed PMID: 25384431; PubMed Central PMCID: PMC4543410. 7: Padhi D, Harris R, Sullivan JT. Effects of calcium carbonate, sevelamer hydrochloride or pantoprazole on the pharmacokinetics of cinacalcet. Clin Drug Investig. 2014 Aug;34(8):537-44. doi: 10.1007/s40261-014-0206-1. PubMed PMID: 24935051. 8: Yamada S, Tsuruya K, Kitazono T. Regression of tumoral calcinosis after the appropriate control of a deranged mineral and bone metabolism, in conjugation with cinacalcet hydrochloride treatment, in a chronic hemodialysis patient. Ther Apher Dial. 2013 Jun;17(3):348-9. doi: 10.1111/1744-9987.12035. Epub 2013 Mar 28. PubMed PMID: 23735152. 9: Komaba H, Moriwaki K, Goto S, Yamada S, Taniguchi M, Kakuta T, Kamae I, Fukagawa M. Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan. Am J Kidney Dis. 2012 Aug;60(2):262-71. doi: 10.1053/j.ajkd.2011.12.034. Epub 2012 Mar 24. PubMed PMID: 22445709. 10: Nakayama K, Nakao K, Takatori Y, Inoue J, Kojo S, Akagi S, Fukushima M, Wada J, Makino H. Long-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism. Int J Nephrol Renovasc Dis. 2013 Dec 18;7:25-33. doi: 10.2147/IJNRD.S54731. eCollection 2013. PubMed PMID: 24379691; PubMed Central PMCID: PMC3872220. 11: Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*. Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation. 2015 Jul 7;132(1):27-39. doi: 10.1161/CIRCULATIONAHA.114.013876. Epub 2015 Jun 9. PubMed PMID: 26059012. 12: Marotta V, Di Somma C, Rubino M, Sciammarella C, Del Prete M, Marciello F, Ramundo V, Circelli L, Buonomano P, Modica R, Vitale M, Colao A, Faggiano A. Potential role of cinacalcet hydrochloride in sporadic primary hyperparathyroidism without surgery indication. Endocrine. 2015 May;49(1):274-8. doi: 10.1007/s12020-014-0381-0. Epub 2014 Aug 15. PubMed PMID: 25123977. 13: Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Dehmel B, Goodman WG, Drüeke TB; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators. Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial. J Am Soc Nephrol. 2015 Jun;26(6):1466-75. doi: 10.1681/ASN.2014040414. Epub 2014 Dec 11. PubMed PMID: 25505257; PubMed Central PMCID: PMC4446874. 14: Yang F, Wang H, Zhao Q, Liu H, Hu P, Jiang J. Determination of cinacalcet hydrochloride in human plasma by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2012 Mar 5;61:237-41. doi: 10.1016/j.jpba.2011.10.022. Epub 2011 Oct 25. PubMed PMID: 22196803. 15: Khan A, Bilezikian J, Bone H, Gurevich A, Lakatos P, Misiorowski W, Rozhinskaya L, Trotman ML, Tóth M. Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery. Eur J Endocrinol. 2015 May;172(5):527-35. doi: 10.1530/EJE-14-0877. Epub 2015 Jan 30. PubMed PMID: 25637076. 16: Yokoyama K. [Vascular Calcification - Pathological Mechanism and Clinical Application - . The effect of cinacalcet on vascular calcification]. Clin Calcium. 2015 May;25(5):729-36. doi: CliCa1505729736. Review. Japanese. PubMed PMID: 25926577. 17: Thiem U, Gessl A, Borchhardt K. Long-term clinical practice experience with cinacalcet for treatment of hypercalcemic hyperparathyroidism after kidney transplantation. Biomed Res Int. 2015;2015:292654. doi: 10.1155/2015/292654. Epub 2015 Mar 10. PubMed PMID: 25861621; PubMed Central PMCID: PMC4377458. 18: Brardi S, Cevenini G, Verdacchi T, Romano G, Ponchietti R. Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study. Arch Ital Urol Androl. 2015 Mar 31;87(1):66-71. doi: 10.4081/aiua.2015.1.66. PubMed PMID: 25847900. 19: El-Shafey EM, Alsahow AE, Alsaran K, Sabry AA, Atia M. Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients. Ther Apher Dial. 2011 Dec;15(6):547-55. doi: 10.1111/j.1744-9987.2011.00994.x. PubMed PMID: 22107691. 20: Wheeler DC, London GM, Parfrey PS, Block GA, Correa-Rotter R, Dehmel B, Drüeke TB, Floege J, Kubo Y, Mahaffey KW, Goodman WG, Moe SM, Trotman ML, Abdalla S, Chertow GM, Herzog CA; EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial Investigators. Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial. J Am Heart Assoc. 2014 Nov 17;3(6):e001363. doi: 10.1161/JAHA.114.001363. Erratum in: J Am Heart Assoc. 2015 Jan;4(1):e000570. PubMed PMID: 25404192; PubMed Central PMCID: PMC4338730.